← Back to All Filings

Exelixis Director Files Intent to Sell $1.03M in Company Stock

Low SignificanceNovember 12, 2025 at 9:33:42 AM EST

EXELIXIS, INC.

$EXEL144CIK: 0000939767

Subscribe to track EXEL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Exelixis Director Files Intent to Sell $1.03M in Company Stock

Company: EXELIXIS, INC. (EXEL) Form: 144 | Filed: 2025-11-12 Significance: Low

Insider: Mary C Beckerle Title: Director | Relationship: Director

Transaction: • Type: Proposed Sale • Shares: 24,622 • Price: ~$41.93 • Value: $1,032,436 • Owned After: Not Disclosed

Key Insight: A director has filed a notice of a proposed sale of shares acquired via restricted stock vesting and an option exercise. The transaction size is negligible compared to the company's market capitalization.

Market Context: The sale represents less than 0.01% of the company's market cap, indicating a routine liquidity event for the insider rather than a change in outlook on the company.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: EXELIXIS, INC. (EXEL)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director at Exelixis has filed a notice of proposed sale for approximately $1.03 million worth of common stock. The transaction is of low significance due to its small size relative to the company's market capitalization.
  • Market Impact: The sale is considered routine and is not expected to have any material impact on the stock price or trading volume.

Company Information

FieldValue
CompanyEXELIXIS, INC.
Ticker SymbolEXEL
CIK0000939767
IndustryBiological Products (No Diagnostic Substances)

Insider Information

FieldValue
NameMary C Beckerle
CIK0001520181
Title/PositionDirector
RelationshipDirector

Transaction Details

FieldValue
Form Type144
Transaction Date2025-11-11
Transaction CodeS
Security TypeCommon Stock
Shares Involved24,622
Price Per Share$41.93 (approx.)
Total Value$1,032,436.33
Shares Owned AfterNot Disclosed
Ownership TypeNot Disclosed

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,032,436.33
% of Market Cap0.0093%
Shares Transacted24,622
% of Shares Outstanding0.0091%
Post-Transaction OwnershipNot Disclosed
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with an $11.10 billion market capitalization, a $1.03 million transaction is immaterial and falls well below the threshold for market-moving events.
  • Ownership Concentration: The filing does not disclose post-transaction ownership, but the sale represents a minuscule fraction (0.0091%) of total shares outstanding.
  • Dilution Impact: Not applicable, as this is a sale of existing shares, not an issuance.
  • Transaction Significance: The sale's value and share count are negligible compared to the company's overall size, classifying it as a routine transaction likely for personal financial management.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is too small to signal any change in insider sentiment or to be absorbed by the market. It represents a tiny fraction of the company's public float and daily trading volume.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The sale size is unlikely to cause any noticeable deviation from average trading volumes.
  • Sentiment Indicator: Neutral. This type of small, planned sale by a non-executive director is common and does not typically influence market sentiment.

Additional Context

Transaction Notes

  • Source of Shares: The shares to be sold were acquired through the vesting of restricted stock (18,838 shares) and a stock option exercise (5,784 shares).
  • Special Circumstances: The filing notes it was submitted a day after the transaction date because the SEC's EDGAR system was closed for a federal holiday.
Topics:#SECFiling#InsiderTrading#EXEL#Exelixis#Form144#InsiderSell#StockMarket#Investing#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.